How to make 'marry me' chicken soup
What is 'marry me' chicken?
Named because it's supposedly so good it will inspire a marriage proposal, this creamy sun-dried tomato chicken recipe has been all over our social media feeds for a while now. It's usually made with chicken breasts and lots of Italian-esque ingredients like garlic, basil and even pasta.
It gives me everything I love about a tangy tomato dish, along with the richness of a creamy sauce. It also looks so good with its bright rose-red coloured sauce and golden chicken, I just want to dive right into it.
A new twist on 'marry me' chicken
Now that we're well and truly into the cooler months, I thought: why not transform this main meal into a hearty soup? You don't even need to serve it with bread (although that's totally an option, too), because it's jam-packed with pasta and chicken, as well as baby spinach for a little extra goodness.
There'll be no complaints about being hungry after a bowl of this:
How to make 'marry me' chicken soup
We've cooked a large chicken breast in the soup, but this recipe is also a great way to use up leftover roast chicken or even a barbecue chicken from the supermarket. Just add in your chopped or shredded chicken at the end to heat it through.
If you're vegetarian, swap out chicken stock for vegetable stock and substitute the chicken for extra green vegies, such as green beans or broccolini. You can add them in along with the sun-dried tomatoes and cook until tender, before adding the spinach.
Cream cheese: our secret ingredient
Instead of regular thickened cream, we decided to add cream cheese to our soup. It adds a slight tanginess, plus extra deliciousness, that cuts through the richness. My top tip for this is to make sure the cream cheese is at room temperature and turn down the heat on the soup before adding the cream cheese.
It definitely takes a little stirring to melt the cream cheese and combine the mixture, but I promise you it will all come together. If you're having any trouble (or, like me, get a little impatient), you can also use a whisk to gently whisk the soup to bring it together.
It's the ideal dish that serves four generously, but if you're not going to eat it all straight away, I think the flavour improves the next day so the leftovers are also great for lunches.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
21 minutes ago
- News.com.au
Biocurious: Clinical trial readouts show road to approval can be as exciting as the destination
In the medical device sector, sometimes trial news can excite investors more than the approval endgame At the application stage, devices have a much higher chance of being approved than drugs Investors can expect news from several companies with pivotal or late-stage trials For a drug or device maker, there's no prouder moment than when a health regulator – especially the US Food & Drug Administration (FDA) – approves their product to be unleashed on unsuspecting patients. It's like watching your kid graduate – and you can even tolerate the long-winded speeches. But don't confuse this coming-of-age moment with being the ultimate share price catalyst. For investors, the 'ker-ching' can be much earlier, such as with trial progress or even the FDA granting permission to begin a study. For instance, PainChek (ASX:PCK) shares had a nice run last October, after a positive validation study that supported the pain measurement app maker's US approval application. In late June Blinklab (ASX:BB1) shares soared after the autism test developer won ethics approval for a 1000-patient US trial. In the case of devices, FDA device approval tends to be less of a dramatic moment than for a drug go-ahead, because the chances of success are much higher. Most applicants avail of the 510(k) route, which means that a device only needs to be substantially equivalent to a legal equivalent. According to the contract research organisation Bioaccess, the FDA processes around 10,000 510(k) applications annually, with an approval rate of around 90%. Review times are also shorter: 120 days compared with 420 days for the de novo (new device) route. Here are some device (or quasi device) plays with advanced trials – typically- pivotal ones – that could move the share price dial. Emvision runs with Emu trial EMvision Medical Devices (ASX:EMV) in enrolling up to 300 suspected stroke victims in a pivotal trial of its stroke detection device Emu, across six local and US sites. Emu is a portable bedside scanning unit that's much lighter than a conventional computed tomography (CT) unit. The company is also developing an even small version, First Responder. As its name suggests, this one's for ambulance use. The trial sites are all high calibre research centres handling high stroke volumes. The stroke patients will receive the standard of care and an Emu scan. Given the device is a trail blazer, Emvision is girding for approval under the de novo route. After that, the company hopes the agency will approve First Responder approval under the 510(k) channel. Emu/First Responder will determine whether a stroke is a blockage (ischaemic)or a bleed (hemorrhagic). This will decide the type of treatment and it's crucial to get the diagnosis right. The company expects a six-to-12-month recruitment period. Micro-X also is on strike with strokes Meanwhile, x-ray imaging house Micro-X (ASX:MX1) plans to launch trails of its portable stroke unit, Head CT, across three local hospitals in the current half. The trials will entail suspected stroke victims being subject to standard CT imaging, then overlaid with the Micro-X scan that deploys a more effective 'cold cathode' method. Aiming for 'several hundred' scans, the studies only need to prove that the Micro-X tech is just as good as the conventional ones, Funded by $8 million from the Australian Stroke Alliance, the study supports a proposed 510(k) application next year, in view of a US launch in 2027. The company expects the trials to run for nine months. Micro-X had multiple applications for its tech, bomb and baggage screening. As part of a 'strategy re-set' the company is focused on medical applications. Micro-X has commercialised two mobile digital radiology devices: the first-generation Nano and a sturdier iteration called Rover. Heart patients move like Jagger In the past, heart patients too old or too sick for surgical aortic valve replacement – or open-heart surgery – in effect were given a death sentence. Transcatheter Aortic Valve Replacement (TAVR) procedures enable malfunctioning valves to be replaced in a non-invasive, 20-minute procedure. TAVR recipients include Arnold Schwarzenegger and Mick Jagger – and they're still rockin'. TAVR also applies to replacing artificial valves that have an effective operating life of five years or so. Anteris Technologies (ASX:AVR) is on track to commence a pivotal trial of its Duravr device in the current quarter, pending FDA approval. The company says it's qualified 79 sites globally for the trial, which will enroll patients with a 'broad array of risk profiles'. The trial will be designed to provide the 'primary clinical evidence' for the FDA to mull premarket approval. In parallel, Anteris is pursuing European clearance. More than Imagion-ation Shares also can pop on the strength of trial approval alone. In the drug/device sphere, Imagion Biosystems (ASX:IBX) awaits clearance to carry out a phase II study of its cancer imaging agent, Magsense for Her-2 positive beast cancers. For use with magnetic resonance imaging (MRI), Magsense improves cancer detection by adding 'molecular specificity'. In lay terms, this avoids painful, error-prone biopsies. This month, Imagion formed an alliance with Michigan's Wayne State University School of Medicine. In part, the institution's MRI gurus will help to devise an optimal dose to be used in the study. Trip the light fantastic Invion (ASX:IVX) highlights how the trial journey, rather than the destination can evoke investor excitement. Invion is advancing photodynamic therapy (PDT) for tumor types including non-melanoma skin cancers and ano-genital cancers. Someone has to do it. The idea is that light-activated photosensitisers leave the healthy tissue unharmed, but zap the diseased stuff. Thus, PTD is a promising non-toxic, non-invasive alternative to chemotherapy, radiation or surgery. Invion shares early last December rocketed more than 300% after the company said it had enrolled its first patient in its Queensland based phase I/II skin cancer trial. The adaptive study now is poised to enter is second stage. The next Sirtex? OncoSil Medical (ASX:OSL) is equated with a less developed version of the targeted liver cancer radiation treatment house Sirtex, acquired for $1.9 billion in 2018 by Chinese interests. Relative commercial immaturity aside, Oncosil targets the difficult pancreatic cancer. Oncosil is trialling its eponymous targeted treatment with the standard-of-care chemo, Folfirinix. The study, TRIPP-FFX, has completed recruitment and investors should expect data in early 2026. The study pertains to patients with locally advanced pancreatic cancer. The trial has recruited 'at least' 88 patients across 15 local and European hospitals. So - there you have it. While bonanza share gains are never guaranteed, investors know where to look for surprise pit stops along the circuitous approval journey.
ABC News
21 hours ago
- ABC News
Microplastics are in our food, water and air. How can we minimise our exposure to them?
The scourge of plastic pollution will continue to grow, at least for now, after talks to strike a global treaty fell apart this month. It was the sixth round of such negotiations in three years, but despite a last-ditch scramble on Friday, delegates could not reach agreement. Meanwhile, new research continues to expose plastic's quiet presence in our food, tap water and the air we breathe. A study published last month found higher-than-expected levels of inhalable plastic particles in a handful of apartments and cars in France. Recent Australian research found even compost contains teeny plastic fragments, which may eventually make their way into agricultural soils and food crops. These are a couple of the latest studies into microplastics: fragments or fibres of plastic between a micron (one millionth of a metre) up to 5 millimetres in size. Microplastics can be created as a result of larger pieces of plastic shedding or breaking apart, or be added to products, such as plastic powders added to some cosmetics. Along with microplastics, there are also nanoplastics. These are plastic particles less than a micron wide. For context, a human hair is about 50 microns in diameter. Being so tiny, nanoplastics might more easily infiltrate human cells and tissues such as our blood, "so they're the ones scientists are interested in", University of Queensland microplastics researcher Cassandra Rauert said. So considering micro- and nanoplastics are everywhere, from the summit of Everest to the deepest ocean, how can we minimise our exposure without living in a cave? The short answer is: we don't yet know. Part of that stems from the fact that we don't know a whole lot about microplastics in general, such as where they come from, how many are in our environment, how they might get into our body, what they do once they're in there, and how much we excrete. "Unfortunately, microplastics is a very new field of research," Dr Rauert said. Compared to other everyday pollutants such as pesticides, scientists don't have a good handle on the potential effects of microplastic or nanoplastic exposure. And current techniques to identify micro- and nanoplastics in various organs "are not perfect". "We really don't have good data showing that plastics are ending up in our brains or our liver or our placenta and things like that. "There's a lot of reactive media to those studies and it's causing a lot of concern, which is very understandable, but … we really don't have a good grip on if plastics are actually getting into our bodies yet." So what do we know? More research needs to be done, but it seems that micro- and nanoplastics can generate inflammation, Dr Rauert said. It's not just the physical presence of plastic particles in the body that may affect our health — it's also the chemicals they bring with them, she added: "You're getting a double hit when you're exposed to these things." Such chemicals can be picked up by plastic particles from the environment, or are additives used during manufacturing that make the plastic more malleable, for instance. These chemicals can disrupt hormones, and "there's evidence coming out now that they're linked to type 2 diabetes", Dr Rauert said. "It's these chemicals that we … are more concerned about exposure to [than the plastic itself]." Despite not yet having definitive evidence that microplastics cause harm to our health, researchers suggest avoiding them as much as possible. That can be hard, considering just how much plastic is all around us all the time. When it comes to food, there is some good news: there's probably less plastic in what we eat than originally feared. One of Dr Rauert's students surveyed food a typical Australian would buy from the supermarket and found low concentrations of nano- and microplastics in them. Any plastic present in food probably comes from the packaging around it. But it's what we do with the food when we bring it home that can contribute to microplastic levels, Dr Rauert added. "If you're using a plastic chopping board, every time you use that [and] you can see it's deforming and degrading as you're using it, there are small pieces of plastic that are going to be coming off that board and end up in the food you're eating." The same goes with plastic ladles and the like. So if possible, try to use wooden chopping boards and metal or wood utensils. Tap water is a potentially bigger source of microplastics than food. These plastic particles can come from any number of sources, from the water treatment process to the PVC pipes that plumb your home. Putting tap water through a filter may be helpful in removing some of the larger microplastics, Dr Rauert said, even if some of the smaller microplastics and nanoplastics slip through. "I reckon in the next couple of years there probably will be some [microplastic-filtering devices] on the market." The air inside our home and the dust that settles on surfaces could well be teeming with micro- and nanoplastics small enough to get into our lungs. Synthetic textiles such as polyester and nylon shed tiny fragments and fibres of plastic, and they are found everywhere from furniture to clothes to manchester and carpet. "A lot of our carpets are polypropylene, so when pieces of the carpet are just wearing off over time, then you're getting small pieces of polypropylene in the air," Dr Rauert said. It might sound boring, but wiping down dusty surfaces and vacuuming regularly can reduce microplastics in your home. Another big source of microplastics in the home, Dr Rauert said, is the clothes dryer, especially if you use it to dry synthetic materials. As they tumble in the hot air, synthetic materials release plastic fibres that aren't captured by the dryer filter. And if that hot air blows out into your home, it carries all those fibres with it. It's often not available to people in apartments, but having a dryer that exhausts to the outside environment instead of inside your house can help keep microplastics down, as can avoiding using the dryer for synthetic materials altogether. Generally, the air outside has fewer microplastics than indoor air, especially in winter when windows might remain closed to keep the warmth in. So it's worth periodically opening windows and doors to ventilate the air in your home and let microplastics out. While we can take individual action to keep our home environment as microplastic-free as possible, plastic pollution will continue to be a problem until large-scale changes are made, such as tougher action from governments, Dr Rauert said. "There are small things we can do, but we really need a bigger, collective global effort to try and really cut down the amount of unnecessary plastic that we keep on producing every year. "You don't actually consider how much plastic you use in your everyday life. It's always there. It's just you don't think about it." For more on microplastics, check out the full episode of Lab Notes.
SBS Australia
3 days ago
- SBS Australia
Palestinian woman evacuated to Italy in a severely emaciated state dies in hospital
A young Palestinian woman who was flown from Gaza to an Italian hospital in a severely emaciated state for treatment has died, the hospital said. The 20-year-old, identified by Italian media reports as Marah Abu Zuhri, arrived in Pisa on an Italian government humanitarian flight overnight Wednesday-Thursday. The University Hospital of Pisa said she had a "very complex clinical picture" and serious wasting, which is when a person has significant weight and muscle loss. On Friday, after undergoing tests and starting treatment, she died after a sudden respiratory crisis and cardiac arrest, the hospital said. The woman was flown to Italy with her mother on one of three Italian air force flights that arrived this week in Rome, Milan and Pisa, carrying a total of 31 patients and their companions. The Italian humanitarian convoy included three special flights provided by the Italian Air Force and transported dozens of patients from Gaza. Source: AFP / Andreas Solaro All the patients suffered from serious congenital diseases, wounds or amputations, the Italian foreign ministry said at the time. So far more than 180 children and young people from Gaza have been brought to Italy since the war began between Israel and Hamas. The head of the Tuscany region, Eugenio Giani, offered his condolences to the woman's family. The hospital did not elaborate on what caused her condition, but Italian news agencies reported that she was suffering from severe malnutrition. US stops issuing visitor visas for people from Gaza The US State Department on Sunday AEST said it was halting all visitor visas for individuals from Gaza while it conducts "a full and thorough" review. The move has been condemned by pro-Palestinian groups. The department said "a small number" of temporary medical-humanitarian visas had been issued in recent days but did not provide a figure. The US issued more than 3,800 B1/B2 visitor visas, which permit foreigners to seek medical treatment in the United States, to holders of the Palestinian Authority travel document so far in 2025, according to an analysis of monthly figures provided on the department's website. That figure includes 640 visas issued in May. The PA issues such travel documents to residents of the Israeli-occupied West Bank and the Gaza Strip. The department's website did not include a breakdown for the two territories. Loomer's statement sparked outrage among some Republicans, with US representative Chip Roy saying he would inquire about the matter and representative Randy Fine describing it as a "national security risk". The Council on American-Islamic Relations condemned the move, saying it was the latest sign of the "intentional cruelty" of the Trump administration. The Palestine Children's Relief Fund said the decision to halt visas would deny access to medical care to wounded and sick children in Gaza . "This policy will have a devastating and irreversible impact on our ability to bring injured and critically ill children from Gaza to the United States for lifesaving medical treatment — a mission that has defined our work for more than 30 years," it said in a statement.
